Literature DB >> 21859946

Cethromycin-mediated protection against the plague pathogen Yersinia pestis in a rat model of infection and comparison with levofloxacin.

Jason A Rosenzweig1, Sheri M Brackman, Michelle L Kirtley, Jian Sha, Tatiana E Erova, Linsey A Yeager, Johnny W Peterson, Ze-Qi Xu, Ashok K Chopra.   

Abstract

The Gram-negative plague bacterium, Yersinia pestis, has historically been regarded as one of the deadliest pathogens known to mankind, having caused three major pandemics. After being transmitted by the bite of an infected flea arthropod vector, Y. pestis can cause three forms of human plague: bubonic, septicemic, and pneumonic, with the latter two having very high mortality rates. With increased threats of bioterrorism, it is likely that a multidrug-resistant Y. pestis strain would be employed, and, as such, conventional antibiotics typically used to treat Y. pestis (e.g., streptomycin, tetracycline, and gentamicin) would be ineffective. In this study, cethromycin (a ketolide antibiotic which inhibits bacterial protein synthesis and is currently in clinical trials for respiratory tract infections) was evaluated for antiplague activity in a rat model of pneumonic infection and compared with levofloxacin, which operates via inhibition of bacterial topoisomerase and DNA gyrase. Following a respiratory challenge of 24 to 30 times the 50% lethal dose of the highly virulent Y. pestis CO92 strain, 70 mg of cethromycin per kg of body weight (orally administered twice daily 24 h postinfection for a period of 7 days) provided complete protection to animals against mortality without any toxic effects. Further, no detectable plague bacilli were cultured from infected animals' blood and spleens following cethromycin treatment. The antibiotic was most effective when administered to rats 24 h postinfection, as the animals succumbed to infection if treatment was further delayed. All cethromycin-treated survivors tolerated 2 subsequent exposures to even higher lethal Y. pestis doses without further antibiotic treatment, which was related, in part, to the development of specific antibodies to the capsular and low-calcium-response V antigens of Y. pestis. These data demonstrate that cethromycin is a potent antiplague drug that can be used to treat pneumonic plague.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21859946      PMCID: PMC3195012          DOI: 10.1128/AAC.00632-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Multidrug resistance in Yersinia pestis mediated by a transferable plasmid.

Authors:  M Galimand; A Guiyoule; G Gerbaud; B Rasoamanana; S Chanteau; E Carniel; P Courvalin
Journal:  N Engl J Med       Date:  1997-09-04       Impact factor: 91.245

2.  Progress on plague vaccine development.

Authors:  Jason A Rosenzweig; Olufisayo Jejelowo; Jian Sha; Tatiana E Erova; Sheri M Brackman; Michelle L Kirtley; Cristina J van Lier; Ashok K Chopra
Journal:  Appl Microbiol Biotechnol       Date:  2011-06-14       Impact factor: 4.813

3.  Comparative efficacies of candidate antibiotics against Yersinia pestis in an in vitro pharmacodynamic model.

Authors:  Arnold Louie; Brian Vanscoy; Weiguo Liu; Robert Kulawy; David Brown; Henry S Heine; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2011-04-12       Impact factor: 5.191

4.  Milestones in progression of primary pneumonic plague in cynomolgus macaques.

Authors:  Frederick Koster; David S Perlin; Steven Park; Trevor Brasel; Andrew Gigliotti; Edward Barr; Leslie Myers; Robert C Layton; Robert Sherwood; C R Lyons
Journal:  Infect Immun       Date:  2010-04-12       Impact factor: 3.441

5.  Comparison of the immune response to three different Yersinia pestis vaccines in guinea pigs and langurs.

Authors:  T H Chen; L E Foster; K F Meyer
Journal:  J Infect Dis       Date:  1974-05       Impact factor: 5.226

6.  Characterization of an F1 deletion mutant of Yersinia pestis CO92, pathogenic role of F1 antigen in bubonic and pneumonic plague, and evaluation of sensitivity and specificity of F1 antigen capture-based dipsticks.

Authors:  Jian Sha; Janice J Endsley; Michelle L Kirtley; Sheri M Foltz; Matthew B Huante; Tatiana E Erova; Elena V Kozlova; Vsevolod L Popov; Linsey A Yeager; Irina V Zudina; Vladimir L Motin; Johnny W Peterson; Kristin L DeBord; Ashok K Chopra
Journal:  J Clin Microbiol       Date:  2011-03-02       Impact factor: 5.948

Review 7.  Cethromycin: a promising new ketolide antibiotic for respiratory infections.

Authors:  Sally Rafie; Conan MacDougall; Charles L James
Journal:  Pharmacotherapy       Date:  2010-03       Impact factor: 4.705

8.  Characterization of the rat pneumonic plague model: infection kinetics following aerosolization of Yersinia pestis CO92.

Authors:  Stacy L Agar; Jian Sha; Sheri M Foltz; Tatiana E Erova; Kristin G Walberg; Wallace B Baze; Giovanni Suarez; Johnny W Peterson; Ashok K Chopra
Journal:  Microbes Infect       Date:  2008-12-03       Impact factor: 2.700

Review 9.  Terrorism from a public health perspective.

Authors:  R Gregory Evans; James M Crutcher; Brooke Shadel; Bruce Clements; Michael S Bronze
Journal:  Am J Med Sci       Date:  2002-06       Impact factor: 2.378

10.  Braun lipoprotein (Lpp) contributes to virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague.

Authors:  Jian Sha; Stacy L Agar; Wallace B Baze; Juan P Olano; Amin A Fadl; Tatiana E Erova; Shaofei Wang; Sheri M Foltz; Giovanni Suarez; Vladimir L Motin; Sadhana Chauhan; Gary R Klimpel; Johnny W Peterson; Ashok K Chopra
Journal:  Infect Immun       Date:  2008-01-28       Impact factor: 3.441

View more
  11 in total

1.  In vitro antibiotic susceptibilities of Yersinia pestis determined by broth microdilution following CLSI methods.

Authors:  Henry S Heine; Jeremy Hershfield; Charles Marchand; Lynda Miller; Stephanie Halasohoris; Bret K Purcell; Patricia L Worsham
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

2.  A non-invasive in vivo imaging system to study dissemination of bioluminescent Yersinia pestis CO92 in a mouse model of pneumonic plague.

Authors:  Jian Sha; Jason A Rosenzweig; Michelle L Kirtley; Christina J van Lier; Eric C Fitts; Elena V Kozlova; Tatiana E Erova; Bethany L Tiner; Ashok K Chopra
Journal:  Microb Pathog       Date:  2012-10-09       Impact factor: 3.738

3.  The effects of modeled microgravity on growth kinetics, antibiotic susceptibility, cold growth, and the virulence potential of a Yersinia pestis ymoA-deficient mutant and its isogenic parental strain.

Authors:  Abidat Lawal; Michelle L Kirtley; Christina J van Lier; Tatiana E Erova; Elena V Kozlova; Jian Sha; Ashok K Chopra; Jason A Rosenzweig
Journal:  Astrobiology       Date:  2013-08-29       Impact factor: 4.335

4.  Intramuscular Immunization of Mice with a Live-Attenuated Triple Mutant of Yersinia pestis CO92 Induces Robust Humoral and Cell-Mediated Immunity To Completely Protect Animals against Pneumonic Plague.

Authors:  Bethany L Tiner; Jian Sha; Duraisamy Ponnusamy; Wallace B Baze; Eric C Fitts; Vsevolod L Popov; Christina J van Lier; Tatiana E Erova; Ashok K Chopra
Journal:  Clin Vaccine Immunol       Date:  2015-10-07

5.  Plague in China 2014-All sporadic case report of pneumonic plague.

Authors:  Yun-Fang Li; De-Biao Li; Hong-Sheng Shao; Hong-Jun Li; Yue-Dong Han
Journal:  BMC Infect Dis       Date:  2016-02-19       Impact factor: 3.090

Review 6.  Antibiotic Therapy of Plague: A Review.

Authors:  Florent Sebbane; Nadine Lemaître
Journal:  Biomolecules       Date:  2021-05-12

7.  Host stress and immune responses during aerosol challenge of Brown Norway rats with Yersinia pestis.

Authors:  Susan T Gater; Kristen N Peters; Andrew G Kocsis; Miqdad O Dhariwala; Deborah M Anderson; Paul E Anderson
Journal:  Front Cell Infect Microbiol       Date:  2012-11-30       Impact factor: 5.293

Review 8.  The effect of low shear force on the virulence potential of Yersinia pestis: new aspects that space-like growth conditions and the final frontier can teach us about a formidable pathogen.

Authors:  Jason A Rosenzweig; Ashok K Chopra
Journal:  Front Cell Infect Microbiol       Date:  2012-08-09       Impact factor: 5.293

9.  Modulation of host immune defenses by Aeromonas and Yersinia species: convergence on toxins secreted by various secretion systems.

Authors:  Jason A Rosenzweig; Ashok K Chopra
Journal:  Front Cell Infect Microbiol       Date:  2013-10-30       Impact factor: 5.293

10.  Immunisation of two rodent species with new live-attenuated mutants of Yersinia pestis CO92 induces protective long-term humoral- and cell-mediated immunity against pneumonic plague.

Authors:  Bethany L Tiner; Jian Sha; Yingzi Cong; Michelle L Kirtley; Jourdan A Andersson; Ashok K Chopra
Journal:  NPJ Vaccines       Date:  2016-10-13       Impact factor: 7.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.